Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

Key Findings

Stop the Drug, Watch the Weight Come Back 🔄

• A review of post-discontinuation data found weight regain after stopping GLP-1 drugs is substantial and front-loaded — most of it happens in the early months after stopping.
• The proposed mechanism: appetite-suppressing drug signals disappear abruptly while hunger hormones like ghrelin rebound, creating a mismatch between biology and behavior. Reduced-intensity maintenance may blunt the rebound, but structured tapering hasn't been formally tested.

GLP-1 Drugs and Cancer Risk: A Credible Signal Emerges 🔬

• A review in the Journal of Clinical Oncology found GLP-1 therapy associated with lower risk across several obesity-related cancers — including gastrointestinal, breast, endometrial, and hematologic malignancies.
• Proposed mechanisms go beyond weight loss and include effects on insulin signaling, inflammation, and immune modulation — though human mechanistic data remain early-stage.

A Rare but Serious Warning: Thiamine Deficiency on GLP-1 Drugs 🧠

• Two separate case reports documented Wernicke's encephalopathy — a severe thiamine-deficiency brain disorder — in patients using semaglutide or tirzepatide, including one case where brain MRI looked normal but a metabolic scan revealed the damage.
• A systematic review of semaglutide-associated cases found the pattern consistent: severe nausea, reduced intake, and nutritional collapse in vulnerable individuals.

Tirzepatide Beats SGLT2 Inhibitors for Fatty Liver Disease 🫁

• A multicenter propensity-matched real-world study found tirzepatide outperformed SGLT2 inhibitors on liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
• A separate real-world study in Communications Medicine confirmed clinical benefits of tirzepatide in this population, including improvements in liver and cardiometabolic markers.

Do GLP-1 Drugs Make You Move Less? 🚶

• A systematic review and meta-analysis of 7 studies covering 924 participants found no statistically significant overall change in physical activity with GLP-1 treatment — but 71% of studies showed numerically lower free-living movement in treated groups.
• One study recorded a significant drop of 1,144 steps per day. Structured exercise participation was unaffected, suggesting the effect is on spontaneous daily movement, not gym sessions.

GLP-1 Drugs After Bariatric Surgery: Meaningful Weight Loss, Fewer Heart Events 💊

• A nationwide U.S. cohort study found that people who used incretin-based therapy after bariatric surgery achieved additional weight loss and lower rates of major adverse cardiovascular events compared to those who didn't.
• The finding matters because weight regain after surgery is common and underaddressed — and this suggests adjunctive drug therapy may extend the cardiovascular benefit of surgery.